BACKGROUND Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB). However, many concerns have been raised about the efficacy of tigecycline treatment as the inconsistent results from previous clinical studies. METHODS This retrospective study evaluated the outcome of adult patients with monomicrobial MDRAB nosocomial pneumonia treated with tigecycline between 2015 and 2017. RESULTS A total of 77 patients was eligible for this study, and the overall clinical success and 30-day survival rates were 70.03 and 70.13%, respectively, however, the microbiological eradication rate was relatively low (48%). Multivariate analysis indicated that shorter duration of tigecycline use associated with increased clinical failure, whereas higher CURB65 scores, mechanical ventilation and tigecycline resistant to MDRAB have significant association with 30-day mortality. CONCLUSIONS Our results suggest that tigecycline is one of the potential choices for the treatment of hospital-acquired pneumonia caused by MDRAB, especially with a MIC≤2 mg/L. In addition, a longer duration of tigecycline treatment may be required to insure better clinical outcomes.

中文翻译：

---

替加环素治疗多药耐药鲍曼不动杆菌引起的医院获得性肺炎的临床经验。

背景技术具有广泛的体外抗菌活性的替吉环素已被广泛用于由多重耐药性鲍曼不动杆菌（MDRAB）引起的医院内肺炎。然而，由于以前的临床研究结果不一致，因此对替加环素治疗的功效引起了许多关注。方法这项回顾性研究评估了2015年至2017年间使用替加环素治疗的成年单微生物MDRAB医院内肺炎患者的结局。结果共有77例患者符合这项研究的要求，总体临床成功率和30天生存率分别为70.03和70.13。但是，微生物的根除率相对较低（48％）。多因素分析表明，使用替加环素的持续时间较短会增加临床失败率，而较高的CURB65评分，机械通气和对MDRAB耐药的替加环素与30天死亡率显着相关。结论我们的结果表明，替加环素是治疗MDRAB引起的医院获得性肺炎的潜在选择之一，尤其是MIC≤2mg / L。另外，可能需要更长的替加环素治疗时间以确保更好的临床结果。